GT Metabolic Solutions, Inc. appears in FDA records at 5450 Quam Ave. NE, Suite 100, St. Michael, MN 55376, the address listed on its 510(k) submission and repeated as the contact address in its instructions for use. The company's documented regulatory footprint in the supplied filings is a single premarket notification, K261467, received May 4, 2026 and decided September 16, 2026 as substantially equivalent under product code SAH, device classification Magnetic Compression Anastomosis System, regulation number 878.4816. The submission was a traditional 510(k) reviewed by the General, Plastic Surgery advisory committee, with a summary included and no third-party review. [1][2][3]

The cleared device and its components

K261467 covers the GT Metabolic Magnet System under two device-name variants, pairing MAG-04 and MAG-05 magnets with the DS-01 delivery system. The company's Magnet System instructions for use enumerate the same component set: GT Metabolic Magnet in 60mm (MAG-04) and 70mm (MAG-05) sizes, the GT Metabolic Delivery System DS-01, and GT Metabolic Laparoscopic Positioning Devices PD-12, PD-18, PD-21, PD-24 and PD-27. The FDA classification record lists the device class as 2 and the medical specialty as General, Plastic Surgery. [1][2][3]

A separate Summary of Safety and Clinical Performance document describes a broader magnet family, adding MAG-01 (40mm) and MAG-02 (50mm) alongside MAG-04 and MAG-05, plus an accessory GT Metabolic Magnetic Retrieval Device. That document states the intended purpose as creating a new connection in the small intestines and/or between the stomach and small intestine using two magnetic devices, a procedure it calls magnetic compression anastomosis. The SSCP's wider component list should not be read as additional FDA clearances. [4][5]

Filing scope and review details

The supplied portfolio snapshot, retrieved November 20, 2026, links one record, a 510(k) with decision SESE; the record sample contains that same single entry, K261467, so collection and sample counts coincide at one. This is a snapshot of supplied filings, not a statement of total company portfolio, sales or safety performance. The FDA record shows a decision date of September 16, 2026, a decision description of Substantially Equivalent, clearance type Traditional, third-party flag N, and no combination product or authorized predetermined change control plan. [1][3]

The FDA premarket notification page for K261467 carries a page update date of November 16, 2026 and links to a clearance document and to a ClinicalTrials.gov study identifier. The public documents do not include the contents of either linked item, so study design, endpoints and results remain unknown here. [3]

Related MagDI documentation

Separate from the Magnet System, GT Metabolic publishes instructions for a MagDI System, Generation 2, listing MAG-01 and MAG-02 magnets with the same DS-01 delivery system and PD-series positioning devices. A product page states that the second-generation MagDI System with 40mm and 50mm DI magnets received U.S. FDA 510(k) clearances in October 2024 and February 2025 under K242086 and K243359, and cites a published side-to-side magnetic duodeno-ileostomy case series. Those clearances are not part of the supplied portfolio snapshot and are reported here only as the company's own published statements. [6][8]

The company's website describes magnetic compression anastomosis as incisionless, sutureless and staple-free, and references a prospective single-center 15-patient study published in JACS. These are company-published characterizations; the underlying publication is not among the public documents, and no efficacy or safety conclusion is drawn from them. [6][9]

Training, labeling and identity boundaries

The SSCP states that the system is available only for use by doctors experienced in anastomosis procedures and in use of the device, and that new users receive the instructions for use and proctoring by an already-trained surgeon. The instructions for use list customer service contact details and the St. Michael, Minnesota address. That address is the FDA filing and labeling contact address; the sources do not establish it as a corporate headquarters, and no parent, brand or ownership relationship is verified in the public information. [2][5][7]